Domestic water hardness, genetic risk, and distinct phenotypes of cardiovascular disease.

Aims: The study aimed to investigate the association between domestic water hardness and the incidence of AF and the interaction effects between water hardness and genetic susceptibility to incident AF risk. As a secondary objective, its associations with incident heart failure (HF), coronary heart disease (CHD), and stroke were measured.

Methods: The UK Biobank is a prospective cohort study comprising over 500,000 participants recruited in the United Kingdom between 2006 and 2010, aged 37 to 73 years.

Encapsulation of FeS within N/S-Doped bamboo-like carbon nanotubes for facilitated rapid catalytic conversion of polysulfides in high-performance lithium-sulfur batteries.

Lithium-sulfur batteries (LSBs) are considered to be competitive next-generation electrochemical energy storage devices, but their practical application is severely hampered by the shuttle effect and slow redox kinetics of soluble lithium polysulfides (LiPSs). To address this challenge, FeS encapsulated within N/S co-doped bamboo-like carbon nanotubes (FeS/NSC) is synthesized via a pyrolysis sulfidation process, and act as a coating separator for LSBs. The 1-dimensional (1D) S and N co-doped carbon substrate materials can act as conductive networks, exposing more adsorption sites and enhancing the capture of LiPSs.

Modulating d-orbital electronic configuration of magnetic iron sulfide nanocrystals for maximized treatment efficiency of chromium-contaminated water.

Hexavalent chromium (Cr(VI)) is one of the most rigorously regulated contaminants frequently detected in surface and groundwater. Magnetic iron sulfides are naturally abundant, environmentally friendly materials ideal for the removal of Cr(VI) from contaminated water, but the high-spin states of Fe(III) ions limits their adsorption affinity. Herein, we develop a heteroatom-doping approach to boost the Cr(VI) removal efficacy of greigite.

A targeted MAVS fusion protein for controlled innate immune activation and antitumor therapy.

Targeted therapies leveraging the innate immune system are emerging as promising cancer treatments. The mitochondrial antiviral signaling protein (MAVS) plays a crucial role in initiating innate immune responses, but its clinical use is limited by the risk of uncontrolled activation and systemic toxicity. To address this, we developed a novel therapeutic agent, the truncated interferon activation switch (TRIAS), combining MAVS truncates with a tumor antigen-targeting single-chain variable fragment (scFv).